Latest Breaking News On - Pre investigational new drug application - Page 1 : comparemela.com

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology

Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

Recognized standard clinical outcome assessment. In March: Tiziana announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences , that. | April 26, 2023

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel

iTolerance, Inc. Completes Pre-IND Meeting with U.S. FDA for Development Program as a Potential Cure for Type 1 Diabetes Without the Need for Life-long Immunosuppression

MIAMI, FL / ACCESSWIRE / March 1, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy